Versatile lyophilizer for research, development or small-scale production

Allows for easy and intuitive scale-up from research.
The Genesis lyophilizer from SP Scientific has been designed with versatility in mind so that this freeze dryer can meet virtually any research, development or small-scale production lyophilization application.
The Genesis is highly configurable and designed to deliver shelf temperatures as low as -70 °C, condenser temperatures to -85 °C, operate in bulk or stoppering configurations. Suitable applications include; pharmaceutical development, tissue processing and banking, natural products research and diagnostics reagent production.
Allowing for easy and intuitive scale-up from research, the Genesis makes the perfect mid-scale lyophilizer. The compact, free-standing, mobile design enables the system to be optimally configured to almost any application. Ergonomic profiling allows easy inspection of the vacuum pump and facilitates quick and trouble-free oil changes. For applications where a sterile environment is critical, an easy-to-install clean room version of the Genesis lyophilizer is also available.
The product chamber, shelves and condenser chamber are made of durable 316L stainless steel, with a squared product chamber that ensures easy cleaning and maximum shelf area. A 4-inch diameter port increases vapour flow from the product to the condenser chamber maximising system productivity. Reliable refrigeration systems with proven CFC-free refrigerants allow Genesis Lyophilizers to achieve a wide range of temperatures enabling freeze drying of all sample types.
The Genesis has a range of powerful control options which allow every aspect of the freeze-drying process to be monitored and controlled. Multiple stage freezing and drying steps can be programmed to enable the best results to be obtained from any product. Controls range from the simple Wizard microprocessor control system to a fully 21 CFR part 11 compliant PC-based control system.
The Genesis is available with up to six bulk drying shelves and five vial processing shelves. An expanded range of shelf arrangements, available with a shelf latching kit, allows you to configure it to process a wide variety of vial sizes, with stoppering an option.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance